Member Info for Bella6532

'Dox concentration was only detected in FAP enzyme.' So does this mean there was no leaching out afterwards which is what biopsies will have confirmed? If so that's this is going to be the key to full success...

https://www.aacr.org/meeting/aacr-annual-meeting-2022/information-for-presenters/

You get to stand by your Poster and have a few minutes to discuss with passers by...think it's 10 mins max. That's how you present at a Poster Presentation.

Sorry Watching 2...the AACR is in New Orleans (Louisiana) so it's +6 hrs...derrrr

Watching2...it's CT (Central Time)...Five states are in both the eastern and central time zones. Those are Florida, Indiana, Kentucky, Michigan and Tennessee...There's a 5 hour time difference between Florida and UK so add 5 hours to below times to get time in UK...it's after markets close so you won't gt anything until tomorrow unless it's posted up on the AACR site or social media. To be honest I would be very surprised if the data is going to be hugely significant to the SP. Far more significant would be other news we are waiting for...

'We will be presenting our poster (abstract number 1815) 'AVA6000, a novel preCISION medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage' on Monday 1:30pm – 5:00pm CT. #AACR22'

106.69...lubbly jubbly...

'We will be presenting our poster (abstract number 1815) 'AVA6000, a novel preCISION medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage' on Monday 1:30pm – 5:00pm CT. #AACR22'

'Pharma Licensing: Why & How?
The development of new drugs is becoming more expensive and needs infrastructure and efficient resources so, licensing collaborations are becoming a favorable option for many global pharmaceutical companies. These licensing options help companies offset to research and development investments and bypass the cumbersome innovation and development process.
As per the global data, in the pharmaceutical industry, the value of the licensing deal exceeded USD 40 billion in 2020. And from this data, the cancer-related assets account for more than half, with four in the cancer immunotherapy area. The complete cancer deals have a value of almost $24 billion out of which a total of just over $40 billion overall.
In the year 2020, here are the top 15 licensing deals between the global pharma players.

AstraZeneca/Daiichi Sankyo
Merck & Co/Seattle Genetics
AbbVie/Genmab
Biogen/Sage Therapeutics
Biogen/Sangamo
Sanofi/Nurix
Merck & Co./Astex/Taiho
Biogen/Denali
Innovent Biologics/Roche
CSL Behring/uniQure
Neurocrine/Takeda
Alnylam/Blackstone
AbbVie/I-Mab
Roche/Blueprint
Eli Lilly/Innovent

Licensing novel molecules and technologies is a relatively new evolving scenario in the global pharma Industry. It helps pharma companies formulate new product strategies having aggressive growth plans at the national and global levels.
There are many key reasons why the innovators (pharmaceutical, biotechnology, or any medical equipment developers) consider this method to move their invention forward.
Some reasons are
To simplify their expansion operations into new markets without having to do it themselves, or
To increase sales or merely to spread the product’s image to a different geographic location.'
https://credevo.com/articles/2021/06/25/pharma-licensing-why-how/

For those who may not have read the full 2020 Annual Report it really is worth a read and for those who did read it a while back it's well worth reading to compare with what we now know has taken place/ been achieved.

https://avacta.com/wp-content/uploads/2021/05/Avacta-ARA-2020.pdf

If AVA6000 works/ shows good results by this Summer then surely it will lead to TMAC push because this is where the real financial goals lie...

If the beans were financially significant we would have been told already...
It's just a bit more pre-clinical stuff which AS said they would put in layman's terms for us mere mortals..

Next Thursday...
'Copies of the poster will be available on Avacta's website following the conference at: https://avacta.com/investors/documents-presentations/

New shares incoming...wink wink...
Friendlies might be happy to sell at these prices with a wink the price just might dropped when new shares become available so they can buy back...
Just a thought...

gmcc...'Anyway Avacta should be consistent - will ask Avacta'...GL with that one gmcc...unless you have an in??!!!

Mmmmm...I posted quite a snotty question about the deal with Moderna being dropped/not mentioned any more in the Investor Meet Q&A section ...wonder if that had anything to do with the changes... !!!
I also expressed concerns over late posting of Answers to Questions from 30 Sept Presentation...
And my concerns over the appointment of FTI Consulting who don't appear to want to engage with shareholders as our only point of contact...
Just had a bit of a bee in my bonnet...

Way to go Mr R...best of luck with your business and hope to see you back here ASAP...

1.2m shares traded in first 10min...

Zoom001...it's now 104...so cracked...

Thought we might have cracked it on Tues...bit late...haha

https://credevo.com/articles/2021/06/25/pharma-licensing-why-how/

Haha...keep up Avacta...I wonder if this would have been RNSs if it hadn't been found and posted up on here...insert cheeky smile here...

If the data is financially significant they will have to share it with with the wider market.